Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
February 04, 2021 16:30 ET
|
Sarepta Therapeutics, Inc.
The four winning lesson plans are now available on sharemylesson.com Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 29, 2021 20:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021...
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
January 13, 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for...
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 08, 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
January 07, 2021 16:05 ET
|
Sarepta Therapeutics, Inc.
-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- --...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2020 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020...
Sarepta Therapeutics Announces Executive Management Changes
December 14, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Ian Estepan named chief financial officer-- Dallan Murray named chief commercial officer-- Louise Rodino-Klapac, Ph.D., named chief scientific officer-- Ty Howton, general counsel, to retire from...
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
December 07, 2020 08:55 ET
|
Sarepta Therapeutics, Inc.
-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than...
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
December 04, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2020 18:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020...